AXA Framlington Biotech Z Inc (FUND:BRJZVL2) - Fund price


Fund Report

AXA Framlington Biotech Fund Z INC

Key Stats
Morningstar® CategorySector Equity Biotechnology
Manager NameLinden Thomson
Inception Date19/01/2015
NAV 18/10/2019GBX 106.40
Day Change0.57%
12 Month Yield0.00%
ISINGB00BRJZVL27
Dividend FrequencySemi-Annually
Net Assets (mil) 30/09/2019363.72 GBP
Wrapper AvailabilityAll
Our Minimum Initial Investment1.00 Share
Pricing FrequencyDaily
Dealing Cut off Time11:00:00
Regular InvestmentYes
Actual Initial Charge0.00%
Exit Charge-
Custody ChargeYes
Ongoing Cost0.83%
AMC0.75%
Fund Rebate-

Morningstar Rating™

StarRatingValueLabel_3

Morningstar Sustainability Rating

Average

Average


Sustainability Rating as of 31/08/2019

Benchmarks

Fund Benchmark

NASDAQ Biotechnology TR USD

Morningstar® Benchmark

NASDAQ Biotechnology TR USD

Growth Of 10,000 (GBP) 30/09/2019

How has this security performed
201420152016201720182019
Fund45.1812.26-4.969.64-6.415.68
Category38.5413.41-3.9610.29-7.966.70
Benchmark42.7618.24-6.1811.10-3.206.66
  • Fund: AXA Framlington Biotech Fund Z INC
  • Category: Sector Equity Biotechnology
  • Benchmark: NASDAQ Biotechnology TR USD
Trailing Returns % (GBP) 18/10/2019
FundCatBmark
YTD4.117.044.70
3 Years Annualised2.513.823.35
5 Years Annualised7.007.668.12
10 Years Annualised14.6014.7917.61

Morningstar SRRI

Lower Risk
Higher Risk
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Potentially Lower ReturnsPotentially Higher Returns
Source: Morningstar

Investment Objective

The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Fund may also invest in other transferable securities and units in collective investment schemes. The Fund may use derivatives for Efficient Portfolio Management. Use may be made of borrowing, cash holdings, hedging and other investment techniques permitted in the applicable Financial Conduct Authority rules.

Portfolio Profile30/09/2019

Morningstar Style Box®

Equity Style

Large, Mid, SmallSize
Value, Blend, Growth
Style
Top Holdings
NameSector%
IncreaseDecreaseNew since last portfolio
Amgen Inc Healthcare8.71
Alexion Pharmaceuticals Inc Healthcare6.62
DecreaseGilead Sciences Inc Healthcare6.59
DecreaseBiogen Inc Healthcare6.34
Biomarin Pharmaceutical Inc Healthcare4.19
Asset Allocation %
LongShortNet
Stocks95.100.0095.10
Bonds0.000.000.00
Cash4.480.124.36
Other0.560.010.55
Top Stock Regions
Region%
United States83.65
Eurozone5.54
Europe - ex Euro4.12
Japan3.27
Asia - Emerging2.09
Top Stock Sectors
Stock Sector%
Healthcare99.74
Industrials0.23
Basic Materials0.02
Financial Services0.00
Real Estate0.00
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.